RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Tocilizumab Significantly Reduces Flares in Polyarticular Juvenile Idiopathic Arthritis
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 19
SP 13
OP 14
DO 10.1177/155989771219008
UL http://mdc.sagepub.com/content/12/19/13.abstract
AB Treatment with tocilizumab, a humanized monoclonal antibody that interrupts interleukin-6-mediated signaling, results in meaningful improvement of polyarticular-course juvenile idiopathic arthritis following methotrexate failure, with treatment responses maintained to at least 40 weeks. This article discusses findings from the A Study of Tocilizumab in Patients with Active Polyarticular-Course Juvenile Idiopathic Arthritis [CHERISH; NCT00988221] trial.